These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 27260087)

  • 21. In vitro evaluation on novel modified chitosan for targeted antitumor drug delivery.
    Qu D; Lin H; Zhang N; Xue J; Zhang C
    Carbohydr Polym; 2013 Jan; 92(1):545-54. PubMed ID: 23218334
    [TBL] [Abstract][Full Text] [Related]  

  • 22. miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer.
    Hu Y; Xu K; Yagüe E
    Breast Cancer Res Treat; 2015 Jun; 151(2):269-80. PubMed ID: 25900794
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
    Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
    Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Upregulation of miR-195 increases the sensitivity of breast cancer cells to Adriamycin treatment through inhibition of Raf-1.
    Yang G; Wu D; Zhu J; Jiang O; Shi Q; Tian J; Weng Y
    Oncol Rep; 2013 Aug; 30(2):877-89. PubMed ID: 23760062
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bufalin loaded biotinylated chitosan nanoparticles: an efficient drug delivery system for targeted chemotherapy against breast carcinoma.
    Tian X; Yin H; Zhang S; Luo Y; Xu K; Ma P; Sui C; Meng F; Liu Y; Jiang Y; Fang J
    Eur J Pharm Biopharm; 2014 Aug; 87(3):445-53. PubMed ID: 24846793
    [TBL] [Abstract][Full Text] [Related]  

  • 26. miR-200b and miR-200c as prognostic factors and mediators of gastric cancer cell progression.
    Tang H; Deng M; Tang Y; Xie X; Guo J; Kong Y; Ye F; Su Q; Xie X
    Clin Cancer Res; 2013 Oct; 19(20):5602-12. PubMed ID: 23995857
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction of the mesenchymal to epithelial transition by demethylation- activated microRNA-200c is involved in the anti-migration/invasion effects of arsenic trioxide on human breast cancer cells.
    Si L; Jiang F; Li Y; Ye X; Mu J; Wang X; Ning S; Hu C; Li Z
    Mol Carcinog; 2015 Sep; 54(9):859-69. PubMed ID: 24729530
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chitosan polyplex nanoparticle vector for miR-145 expression in MCF-7: Optimization by design of experiment.
    Tekie FS; Atyabi F; Soleimani M; Arefian E; Atashi A; Kiani M; Khoshayand MR; Amini M; Dinarvand R
    Int J Biol Macromol; 2015 Nov; 81():828-37. PubMed ID: 26365019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MicroRNA-21 modulates chemosensitivity of breast cancer cells to doxorubicin by targeting PTEN.
    Wang ZX; Lu BB; Wang H; Cheng ZX; Yin YM
    Arch Med Res; 2011 May; 42(4):281-90. PubMed ID: 21820606
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effect of miR-15a on induction of apoptosis in breast cancer MCF-7 cells].
    Liu YH; Hong LQ; Yu WQ; Li XY; Zheng XY
    Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):827-30. PubMed ID: 22335947
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-cancerous efficacy and pharmacokinetics of 6-mercaptopurine loaded chitosan nanoparticles.
    Kumar GP; Sanganal JS; Phani AR; Manohara C; Tripathi SM; Raghavendra HL; Janardhana PB; Amaresha S; Swamy KB; Prasad RG
    Pharmacol Res; 2015 Oct; 100():47-57. PubMed ID: 26232590
    [TBL] [Abstract][Full Text] [Related]  

  • 32. miR-193b Modulates Resistance to Doxorubicin in Human Breast Cancer Cells by Downregulating MCL-1.
    Long J; Ji Z; Jiang K; Wang Z; Meng G
    Biomed Res Int; 2015; 2015():373574. PubMed ID: 26526790
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MiR-222 promotes drug-resistance of breast cancer cells to adriamycin via modulation of PTEN/Akt/FOXO1 pathway.
    Shen H; Wang D; Li L; Yang S; Chen X; Zhou S; Zhong S; Zhao J; Tang J
    Gene; 2017 Jan; 596():110-118. PubMed ID: 27746366
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro silencing effect of chitosan nanoplexes containing siRNA expressing vector targeting VEGF in breast cancer cell lines.
    Salva E; Akbuğa J
    Pharmazie; 2010 Dec; 65(12):896-902. PubMed ID: 21284259
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The interactions between MicroRNA-200c and BRD7 in endometrial carcinoma.
    Park YA; Lee JW; Choi JJ; Jeon HK; Cho Y; Choi C; Kim TJ; Lee NW; Kim BG; Bae DS
    Gynecol Oncol; 2012 Jan; 124(1):125-33. PubMed ID: 22015043
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hollow chitosan-silica nanospheres as pH-sensitive targeted delivery carriers in breast cancer therapy.
    Deng Z; Zhen Z; Hu X; Wu S; Xu Z; Chu PK
    Biomaterials; 2011 Jul; 32(21):4976-86. PubMed ID: 21486679
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chitosan derivatives inhibit cell proliferation and induce apoptosis in breast cancer cells.
    Jiang M; Ouyang H; Ruan P; Zhao H; Pi Z; Huang S; Yi P; Crepin M
    Anticancer Res; 2011 Apr; 31(4):1321-8. PubMed ID: 21508382
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor-suppressing roles of miR-214 and miR-218 in breast cancer.
    Liu B; Tian Y; Li F; Zhao Z; Jiang X; Zhai C; Han X; Zhang L
    Oncol Rep; 2016 Jun; 35(6):3178-84. PubMed ID: 27109339
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MiR-125b regulates epithelial-mesenchymal transition via targeting Sema4C in paclitaxel-resistant breast cancer cells.
    Yang Q; Wang Y; Lu X; Zhao Z; Zhu L; Chen S; Wu Q; Chen C; Wang Z
    Oncotarget; 2015 Feb; 6(5):3268-79. PubMed ID: 25605244
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of (153) Sm-folate-polyethyleneimine-conjugated chitosan nanoparticles for targeted therapy.
    Mollarazi E; Jalilian AR; Johari-Daha F; Atyabi F
    J Labelled Comp Radiopharm; 2015 Jun; 58(8):327-35. PubMed ID: 26036233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.